D13 set to demonstrate at Black Dart event

Published 14-SEP-2016 15:42 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Department 13 International (ASX: D13) rallied strongly on Wednesday after the company announced that its proprietary counter drone system, Mesmer, was being demonstrated live at the US Department of Defence Black Dart event this week.

Black Dart is an invitation only event where the US Department of Defence conducts evaluation exercise programs for premier counter drone technology is that detect, identify, track and defeat or disable Unmanned Aerial Systems (UAS).

As can be seen in the five major goals outlined by management for achievement in fiscal 2016, the company is well advanced in meeting milestones, one of which includes validation of its technology at the Black Dart event.

In commenting on this important upcoming opportunity, D13 Chief Executive Jonathan Hunter said, “Black Dart will allow D13 to showcase its dynamic Counter Drone Solution and finalise our path to commercialisation for Version 1 Mesmer, a product with the capability to take positive control of commercial drones”.

Hunter highlighted that Mesmer provides an affordable and effective first line of defence for the detection and identification of unauthorised drones, as well as being able to facilitate the positive control to safe land a drone.

One of the significant points of difference offered by Mesmer is the fact that it does not employ kinetic attacks or jamming.

To provide some background, Department 13 was founded in 2010 by a team of former military operators, scientists and engineers who given their background were well equipped to understand both the practical and technical capabilities required to develop an effective counter drone device.

Importantly, there are numerous revenue streams open to D13 (highlighted below) as it is developing cutting-edge software and communication systems that have the potential to transform the networking and communication fields, as well as current applications in drone defence, mobile phone IT security and secure enhanced android phone systems.

Consequently, with 11 patents and 14 patents applications in the development of wireless protocol manipulation and communication networking software, D13 has the potential to target multiple markets across the civil, military and commercial sectors.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X